RA410/Sly1 suppresses MPP+ and 6-hydroxydopamine-induced cell death in SH-SY5Y cells

被引:20
作者
Bando, Y
Katayama, T
Taniguchi, M
Ishibashi, T
Matsuo, N
Ogawa, S
Tohyama, M
机构
[1] Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Osaka 5650871, Japan
[2] CREST, JST, Kawaguchi, Japan
[3] Dainippon Pharmaceut Co Ltd, Licensing Div, Osaka, Japan
[4] Kanazawa Univ, Sch Med, Dept Neuroanat, Kanazawa, Ishikawa, Japan
基金
日本科学技术振兴机构;
关键词
Parkinson's disease; vesicle transport; MPP; 6-OHDA and cell death;
D O I
10.1016/j.nbd.2004.09.008
中图分类号
Q189 [神经科学];
学科分类号
071006 [神经生物学];
摘要
Parkinson's disease is characterized by selective loss of dopaminergic neurons in the substantia nigra. However, its associated cell death mechanism remains unknown. 1-Methyl-4-phenil-pyridinium (MPP+) and 6-hydroxydopamine (6-OHDA) cause dopaminergic neuronal cell death. Both are widely used to model PD. We investigated the role of a vesicle-transport-related protein, RA410/Sly1, in SH-SY5Y cells to clarify the mechanism of cellular adaptation to MPP+ and 6-OHDA-induced stress. Antisense RA410/Sly1 transformants treated with these toxins displayed reduced viability in comparison with viability of wildtype or RA410/Sly1 sense transformants. Electron microscopy analysis indicated that the ER in MPP+-treated antisense RA410/Sly1 transformants was rapidly disrupted in comparison to wild-type or sense RNA transformants. Cell death induced by MPP+ and 6-OHDA was suppressed in RA410/Sly1 sense transformants through suppression of caspase-2, -3 and -9 activation. These results suggest that RA410/Sly1 plays an important cytoprotective role in MPP+ and 6-OHDA-induced cellular perturbation. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:143 / 151
页数:9
相关论文
共 51 条
[1]
GRP94 (94 kDa glucose-regulated protein) suppresses ischemic neuronal cell death against ischemia/reperfusion injury [J].
Bando, Y ;
Katayama, T ;
Kasai, K ;
Taniguchi, M ;
Tamatani, M ;
Tohyama, M .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2003, 18 (04) :829-840
[2]
150-kDa oxygen-regulated protein (ORP150) functions as a novel molecular chaperone in MDCK cells [J].
Bando, Y ;
Ogawa, S ;
Yamauchi, A ;
Kuwabara, K ;
Ozawa, K ;
Hori, O ;
Yanagi, H ;
Tamatani, M ;
Tohyama, M .
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2000, 278 (06) :C1172-C1182
[3]
Neurodegenerative diseases and oxidative stress [J].
Barnham, KJ ;
Masters, CL ;
Bush, AI .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (03) :205-214
[4]
Experimental models of Parkinson's disease [J].
Beal, MF .
NATURE REVIEWS NEUROSCIENCE, 2001, 2 (05) :325-332
[5]
Blum JD, 2000, J HIGH ENERGY PHYS
[6]
Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins [J].
Butterfield, DA ;
Kanski, J .
MECHANISMS OF AGEING AND DEVELOPMENT, 2001, 122 (09) :945-962
[7]
Choi WS, 1999, J NEUROSCI RES, V57, P86, DOI 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.3.CO
[8]
2-5
[9]
Parkinson's disease: Mechanisms and models [J].
Dauer, W ;
Przedborski, S .
NEURON, 2003, 39 (06) :889-909
[10]
Galvin J E, 1999, Adv Neurol, V80, P313